Form 4: Ionis Pharma Exec Sells Shares After Option Exercise

Ionis Pharmaceuticals' EVP, CLO & General Counsel, Patrick R. O'Neil, sold shares totaling over $1.6 million in late September 2025, following the exercise of stock options under a pre-arranged 10b5-1 trading plan.

Summary

• Patrick R. O'Neil, Executive Vice President, Chief Legal Officer, and General Counsel of Ionis Pharmaceuticals Inc. (IONS), engaged in transactions involving company common stock.
• On September 29, 2025, O'Neil exercised options to acquire 10,473 shares of common stock at an exercise price of $56.78 per share.
• Immediately following the option exercise on September 29, 2025, O'Neil sold 10,473 shares of common stock at a weighted average price of $64.5417 per share, with prices ranging from $64.50 to $64.63.
• On September 30, 2025, O'Neil exercised options to acquire an additional 14,827 shares of common stock at an exercise price of $56.78 per share.
• Following this second option exercise on September 30, 2025, O'Neil sold 14,827 shares of common stock at a weighted average price of $64.6777 per share, with prices ranging from $64.50 to $64.945.
• All sales were conducted pursuant to a Rule 10b5-1 Trading Plan adopted by O'Neil on May 2, 2025.
• After these transactions, O'Neil directly beneficially owns 57,130 shares of common stock and 30,203 non-qualified stock options.

Sentiment

Score: 6

Explanation: The transactions represent a routine exercise of stock options and subsequent sale of shares under a pre-established 10b5-1 trading plan, indicating a planned liquidity event rather than a reaction to new material information. The executive realized a profit from the option exercise.

Positives

• The executive realized a profit from the exercise of stock options and subsequent sale of shares, indicating a successful personal liquidity event.
• The transactions were executed under a pre-established Rule 10b5-1 trading plan, which demonstrates a commitment to compliance and reduces concerns about opportunistic insider trading.

Negatives

• The sale of shares by a high-ranking executive, even if pre-planned, could be interpreted by some investors as a lack of conviction in the company's near-term stock price appreciation, although this is mitigated by the 10b5-1 plan.

Stakeholder Impact

• Shareholders may view the executive's sale of shares as a routine liquidity event, especially given the pre-planned nature under a 10b5-1 plan, which generally mitigates concerns about opportunistic insider selling.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the exercise of stock options and subsequent sale of shares under a pre-established 10b5-1 trading plan. Such transactions are typically for personal financial planning and do not usually signal a change in the company's fundamental outlook or warrant a shift in investment thesis. Therefore, a 'hold' recommendation is appropriate as this event does not provide new information to significantly alter an investment decision.

Keywords

Ionis Pharmaceuticals, IONS, Form 4, Insider Transaction, Stock Options, 10b5-1 Plan, Executive Compensation, Share Sale